Launch of new Company Long Term Incentive Plan

Allergy Therapeutics PLC

04 July 2024

 

    
Allergy Therapeutics plc

("Allergy Therapeutics" or "the Group")

Launch of new Company Long Term Incentive Plan

Grant of Options

Change of Name of Nominated Adviser and Broker

4 July 2024 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that on 26 June 2024 it adopted a new long-term incentive plan ("New LTIP"), with share option awards to be made to key members of Allergy Therapeutics' management team including certain of its persons discharging managerial responsibilities ("PDMRs").

The Group's Remuneration Committee adopted the New LTIP and has granted options to encourage long-term value creation for the Company's shareholders, and so that the individuals identified as key people to lead the business into the future are appropriately incentivised in a manner that aligns with the interests of the Group's stakeholders.

Vesting is conditional on the satisfaction of performance criteria over a three year period. The vesting of any share options is subject to a share price threshold. So long as this share price threshold is exceeded, vesting of 70 per cent. of the award is subject to EBITDA performance and vesting of 30 per cent. of the award is subject to regulatory performance targets.

The following awards have been made in accordance with the New LTIP:

Name	Title	Number of share options granted	Performance period	Vesting Date	Exercise price
Manuel Llobet	Chief Executive Officer	9,650,663	3 years commencing 1 July 2023	30 June 2026	£0.001
Shaun Furlong	Chief Financial Officer	3,809,524	3 years commencing 1 July 2023	30 June 2026	£0.001

The number of Ordinary Shares stated above is the maximum number that could be issued to each PDMR upon full satisfaction of the performance conditions attached to the awards.

The Committee will review the performance conditions at periodic intervals to ensure they remain appropriate. As a result of any such review, the Committee will retain discretion to amend the conditions where appropriate having regard to overall Company performance and wider stakeholder experience.

Change of Name of Nominated Adviser and Broker

The Company also announces that its Nominated Adviser and Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

- ENDS -

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

[phone]

Panmure Liberum (Nominated Adviser and Broker)

Emma Earl, Will Goode, Freddy Crossley, Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

[phone]

ICR Consilium

Mary-Jane Elliott / David Daley / Davide Salvi

[phone]

[e-mail]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations

1	Details of the persons discharging managerial responsibilities / person closely associated
a)	Name	1. Manuel Llobet 2. Shaun Furlong
2	Reason for the notification
a)	Position/status	1.   Chief Executive Officer 2.   Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Allergy Therapeutics plc
b)	LEI	213800PQ7AHK7KGVOE23
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 0.1 pence each
	Identification code	GB00B02LCQ05
b)	Nature of the transaction	Grant of options
c)	Price(s) and volume(s)	Exercise Prices per share Volumes 1. £0.001 2. £0.001 1. 9,650,663 2. 3,809,524
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	27 June 2024
f)	Place of the transaction	Outside a trading venue

 

END